Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
Dr Henrik Björkman will lead the R&D and product supply teams.

As part of his new role at Gyros, Henrik will have responsibility for driving strategic and operational decisions, managing product development, intellectual property, manufacturing, QA, and QC, and will oversee the existing product range. As part of the executive management team Henrik will work closely with marketing and sales departments, reporting to the board of directors.

Henrik joins Gyros from GE Healthcare Life Sciences, where he was most recently Director, MicroCal R&D, leading the MicroCal operation in Northampton, MA. He has many years of experience in senior positions within R&D, technical and management roles, at a range of life science companies from small organizations to larger, industrial enterprises. Henrik holds a PhD in Materials Science and Micro Engineering from Uppsala University.

“The technology developed at Gyros offers an exciting step forward for the biopharmaceutical community,” said Henrik. “I am excited to have the opportunity to support the continued success of the Gyros immunoassay platform.”

Erik Walldén, CEO at Gyros, commented: “We welcome Henrik to Gyros, and look forward to working with him. Bringing extensive experience in product development and manufacturing for globalized, commercial organizations in the life science tools industry, Henrik will be a great asset for the continued development of our microfluidic immunoassay technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros AB, Protein Technologies Merge
Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing
Wednesday, March 16, 2016
Gyros and Tekon Biotech Sign Distribution Agreement
Tekon will distribute Gyros’ immunoassay platform in China, Taiwan & Hong Kong.
Tuesday, April 01, 2014
Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
Gyros AB announced that BioAgilytix Labs has invested in two Gyrolab™ xP workstations to support its bioanalysis services.
Tuesday, November 12, 2013
Dan Calvo Appointed CEO of Gyros AB
Erik Walldén steps down as chief executive officer and president.
Thursday, October 24, 2013
Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors
Dr. Braestrup is a member of the Board of Directors of Bavarian Nordic A/S, Chairman of the Board of Probiodrug AG and a member of the Boards of Santaris Pharma A/S and Evolva Holding SA.
Monday, January 28, 2013
Gyros AB Quality Management System Receives ISO 9001:2008 Certification
Certification reassures customers that they receive consistently high standard of products and services.
Tuesday, December 18, 2012
Gyros Expands Asian Distribution to Singapore
Nanoliter-scale immunoassay platform now available to biopharmaceutical companies in Singapore region.
Thursday, June 07, 2012
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement for Japan
Brings the Gyros nanoliter-scale immunoassay platform to biopharmaceutical and vaccine manufacturers in Japan.
Thursday, July 14, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
Gyros AB announces that GE Healthcare Life Sciences has become the sole distributor for the company’s nanoliter-scale immunoassay platform in Japan.
Tuesday, July 12, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!